Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.

The introduction of oral semaglutide 14mg as a second-line treatment option after metformin is indicated as budget-neutral to slightly budget-inflating for the public pharmaceutical formulary of KSA. The price difference is offset by positive health outcomes and costs. This conclusion was confirmed through a probabilistic sensitivity analysis.